158 related articles for article (PubMed ID: 32703486)
1. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis.
Hu H; Zhou C; Li B; Chen Y; Dai J; Mao Y; Huang T; Yu H; Chen M; Zhao J; Duan S
Pathol Res Pract; 2018 Oct; 214(10):1572-1578. PubMed ID: 30082160
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.
Nilsson TK; Löf-Öhlin ZM; Sun XF
Int J Oncol; 2013 Jan; 42(1):127-33. PubMed ID: 23128528
[TBL] [Abstract][Full Text] [Related]
4. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
Wang HL; Liu P; Zhou PY; Zhang Y
Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
[TBL] [Abstract][Full Text] [Related]
6. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy.
Sun X; Yuan W; Hao F; Zhuang W
Med Sci Monit; 2017 Nov; 23():5389-5395. PubMed ID: 29128865
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
Wang HL; Zhang Y; Liu P; Zhou PY
Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
[TBL] [Abstract][Full Text] [Related]
8. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
9. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
[TBL] [Abstract][Full Text] [Related]
11. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis.
Shi DT; Han M; Gao N; Tian W; Chen W
Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879
[TBL] [Abstract][Full Text] [Related]
12. [Methylation status of PCDH10 and RASSF1A gene promoters in colorectal cancer].
Li M; Yan DG; Liu JL
Zhonghua Yi Xue Za Zhi; 2016 Feb; 96(6):456-9. PubMed ID: 26875923
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
Guo Y; Long J; Lei S
J Cell Physiol; 2019 May; 234(5):7356-7367. PubMed ID: 30370527
[TBL] [Abstract][Full Text] [Related]
14. β-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients.
Chen SP; Wu CC; Huang SY; Kang JC; Chiu SC; Yang KL; Pang CY
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1277-81. PubMed ID: 23009572
[TBL] [Abstract][Full Text] [Related]
15. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
[TBL] [Abstract][Full Text] [Related]
17. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
[TBL] [Abstract][Full Text] [Related]
18. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).
Niu H; Yang J; Yang K; Huang Y
Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283
[TBL] [Abstract][Full Text] [Related]
19. Association Between
Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A
Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003
[TBL] [Abstract][Full Text] [Related]
20. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
